12:00 AM
Mar 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

Merck KGaA gastrointestinal news

Merck's Merck Serono S.A. division launched Calypso Biotech S.A. (Geneva, Switzerland) to develop Merck Serono's preclinical R&D portfolio for gastrointestinal immunological disorders. The newco will continue R&D of an undisclosed preclinical antibody program from Merck Serono in inflammatory...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >